The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Jul. 28, 10:07 PM

Slide #4. Exact Sciences Corporation Secondary Offering

Company: Exact Sciences Corporation (NASDAQ:EXAS)
Date announced: 7/27/2016
Shares Offered: 8,500,000
Date of Pricing: 7/28/2016
Price Per Share: $15.50
Secondary Offering Details: Exact Sciences Corporation (NASDAQ:EXAS) today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, Robert W. Baird & Co. Incorporated and Canaccord Genuity Inc. as underwriters in an underwritten public offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares. -updated 7/28- Exact Sciences Corporation (NASDAQ: EXAS) today announced the upsizing and pricing of its previously announced underwritten public offering of common stock. The Company is selling 8,500,000 shares of common stock through the underwriters at a public offering price of $15.50 per share. The offering was increased to 8,500,000 shares from the previously announced offering of 7,000,000 shares due to market demand. The Company has also granted the underwriters an option to purchase up to 1,275,000 additional shares. The offering is being underwritten by Jefferies LLC and Robert W. Baird & Co. Incorporated, as joint book-running managers of the offering, and Canaccord Genuity Inc., as co-manager of the offering, and is expected to close on or about August 2, 2016, subject to customary closing conditions.

EXACT Sciences is a molecular diagnostics company focused on the detection and prevention of colorectal cancer. Co. has developed a non-invasive screening test called Cologuard®, which is a stool-based DNA screening test designed to detect DNA markers. The Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool from the exfoliation of cells that line the colon. In addition to DNA markers, Co.'s test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test.

EXAS SEC Filing Email Alerts Service

Open the EXAS Page at The Online Investor »

Company Name:  EXACT Sciences Corp.
Website:  www.exactsciences.com
Sector:  Biotechnology
Number of ETFs Holding EXAS:  19
Total Market Value Held by ETFs:  $120.09M
Total Market Capitalization:  $1.59B
% of Market Cap. Held by ETFs:  7.53%
 

Open the EXAS Page at The Online Investor (in a new window) »

July 28, 2016    10:07 PM Eastern
Quotes delayed 20 minutes



Buy (3.00 out of 4)
46th percentile
(ranked lower than approx. 54% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.